Search

Your search keyword '"de Vries, EGE"' showing total 456 results
Start Over Author "de Vries, EGE"
456 results on '"de Vries, EGE"'

101. Expression of macrophage colony-stimulating factor (M-CSF), interleukin-6 (IL-6), interleukin-1 beta (IL-1 beta), interleukin-11 (IL-11) and tumour necrosis factor-alpha (TNF-alpha) in p53-characterised human ovarian carcinomas

Author

Asschert, JGW, Vellenga, E, Hollema, H, van der Zee, AGJ, de Vries, EGE, Guided Treatment in Optimal Selected Cancer Patients (GUTS), Stem Cell Aging Leukemia and Lymphoma (SALL), and Targeted Gynaecologic Oncology (TARGON)

Subjects
p53, CONSTITUTIVE PRODUCTION, GROWTH-FACTOR, human ovarian carcinomas, P53 EXPRESSION, ESCHERICHIA-COLI, SERUM LEVELS, HUMAN-MONOCYTES, cytokine expression, EPITHELIAL CANCER, CELL-LINES, TRANSCRIPTION FACTOR, GENE
Abstract

Ovarian carcinoma is often associated with overexpression of cytokines that may exert autocrine and paracrine growth effects, as well as genetic alterations in (proto)oncogenes and tumour suppressor genes, such as p53. The p53 protein is not only involved in the regulation of cell cycle and apoptosis, it is also involved in the in vitro regulation of IL-6 gene expression. In this study, 30 tumours of patients with a primary diagnosis of human ovarian carcinoma were characterised for p53 expression with immunohistochemistry and analysed for the expression of M-CSF, IL-6, IL-1 beta, IL-11 and TNF-alpha with Northern blotting. Nuclear and cytoplasmic p53 staining was observed in 27% (8/30), cytoplasmic staining in 30% (9/30), and no p53 staining in 43% (13/30) of the tumours. In 70% (21/30) of the tumours, M-CSF mRNA was expressed, in 40% (12/30) TNF-alpha, and in 30% (9/30) IL-6. None of the tumours expressed IL-1 beta or IL-11. The expression of TNF-alpha occurred more frequently in M-CSF positive tumours compared to M-CSF negative tumours (52% (11/21) versus 11% (1/9), P

Published
1997

104. The Carcinoid Syndrome and Angioedema

Author

Wymenga, ANM, de Monchy, JGR, de Vries, EGE, and Guided Treatment in Optimal Selected Cancer Patients (GUTS)

Subjects
ONDANSETRON
Published
1995

105. Long-term results of induction- and intensification chemotherapy supported with autologous bone marrow reinfusion in patients with disseminated or T4 breast cancer

Author

Mulder, NH, Dolsma, WV, Mulder, POM, de Vries, EGE, Willemse, PHB, Sleijfer, DT, Hospers, GAP, and van der Graaf, WTA

Subjects
HIGH-DOSE CHEMOTHERAPY, BREAST CANCER, SURGERY, CHEMOTHERAPY, BONE MARROW AUTOTRANSPLANTATION, THERAPY, RADIOTHERAPY
Abstract

Twenty-nine patients with metastatic or T4 breast cancel who were in pathologically proven complete remission after induction chemotherapy, received intensification chemotherapy with autologous bone marrow support. Twelve patients had T4 breast cancer; 17 had metastatic disease. The median age was 42 years (27-52). Intensification consisted of cyclophosphamide 7 g/m(2) i.v. and etoposide 1.5 g/m(2) i.v, in 24 patients, or thiotepa 800 mg/m(2) i.v. and mitoxantrone 50-75 mg/m(2) i.v. in 5 patients. The median observation is 7 years. Median survival is 36 months Ten year relapse-free survival is 20%. For patients with metastatic disease median survival is 34 months, time to relapse 18 months two patients (12%) have survived disease-free for more than 6 years. The patients with T4 cancer have a median survival of 80 months and a median time to relapse of 53 months; four patients (33%) have survived more than 5 years disease free.

Published
1995

119. Broad phase II and pharmacokinetic study of methoxy-morpholino doxorubicin (FCE 23762-MMRDX) in non-small-cell lung cancer, renal cancer and other solid tumour patients

Author

Bakker, M, primary, Droz, JP, additional, Hanauske, AR, additional, Verweij, J, additional, van Oosterom, AT, additional, Groen, HJM, additional, Pacciarini, MA, additional, Domenigoni, L, additional, van Weissenbruch, F, additional, Pianezzola, E, additional, and de Vries, EGE, additional

Published
1998
Full Text
View/download PDF

126. Fostriecin

Author

de Jong, R S, primary, de Vries, EGE, additional, and Mulder, N H, additional

Published
1997
Full Text
View/download PDF

148. Pharmacokinetics of gemcitabine in non-small-cell lung cancer patients: impact of the 79A<GT>C cytidine deaminase polymorphism.

Author

Maring JG, Wachters FM, Slijfer M, Maurer JM, Boezen HM, Uges DRA, de Vries EGE, and Groen HJM

Abstract

To study the impact of the 79A>C polymorphism in the cytidine deaminase (CDA) gene on the pharmacokinetics of gemcitabine and its metabolite 2',2'-difluorodeoxyuridine (dFdU) in non-small-cell lung cancer (NSCLC) patients. Patients ( n = 20) received gemcitabine 1,125 mg/m2 as a 30 min i.v. infusion as part of treatment for NSCLC. Plasma samples were collected during 0-6 h after gemcitabine administration. Gemcitabine and dFdU were quantified by high performance liquid chromatography with ultraviolet detection. The CDA 79A>C genotype was determined with PCR and DNA sequencing. Gemcitabine was rapidly cleared from plasma and undetectable after 3 h. The allele frequency of the 79A>C polymorphism was 0.40. Diplotypes were distributed as A/A n = 8, A/C n = 8 ,and C/C n = 4. No significant differences were found between the different CDA genotypes and gemcitabine or dFdU AUC, clearance, or half-life. The 79A>C polymorphism in the CDA gene does not have a major consistent and signficant impact on gemcitabine pharmacokinetics. [ABSTRACT FROM AUTHOR]

Published
2010
Full Text
View/download PDF

150. Staging of carcinoid tumours with 18F-DOPA PET: a prospective, diagnostic accuracy study.

Author

Koopmans KP, de Vries EGE, Kema IP, Elsinga PH, Neels OC, Sluiter WJ, van der Horst-Schrivers ANA, Jager PL, Koopmans, Klaas P, de Vries, Elisabeth G E, Kema, Ido P, Elsinga, Philip H, Neels, Oliver C, Sluiter, Wim J, van der Horst-Schrivers, Anouk N A, and Jager, Pieter L

Abstract

Background: To assess individual treatment options for patients with carcinoid tumours, accurate knowledge of tumour localisation is essential. We aimed to test the diagnostic sensitivity of 6-[fluoride-18]fluoro-levodopa ((18)F-DOPA PET), compared with conventional imaging methods, in patients with carcinoid tumours. Methods: In a prospective, single-centre, diagnostic accuracy study, (18)F-DOPA PET with carbidopa pretreatment was compared with somatostatin-receptor scintigraphy (SRS), CT, and combined SRS and CT in 53 patients with a metastatic carcinoid tumour. The performance of all imaging methods was analysed for individual patients, for eight body regions, and for the detection of individual lesions. PET and CT images were fused to improve localisation. To produce a composite reference standard, we used cytological and histological findings; all imaging tests, including secondary assessments for newly found lesions; follow-up; and biochemical data. Sensitivities were calculated and compared. Findings: In patient-based analysis, we recorded sensitivities of 100% (95% CI 93-100) for (18)F-DOPA-PET, 92% (82-98) for SRS, 87% (75-95) for CT, and 96% (87-100) for combined SRS and CT (p=0.45 for (18)F-DOPA PET vs combined SRS and CT). However, (18)F-DOPA PET detected more lesions, more positive regions, and more lesions per region than combined SRS and CT. In region-based analysis, sensitivity of (18)F-DOPA PET was 95% (90-98) versus 66% (57-74) for SRS, 57% (48-66) for CT, and 79% (70-86) for combined SRS and CT (p=0.0001, PET vs combined SRS and CT). In individual-lesion analysis, corresponding sensitivities were 96% (95-98), 46% (43-50), 54% (51-58), and 65% (62-69; p<0.0001 for PET vs combined SRS and CT). Interpretation: If the improved tumour localisation seen with (18)F-DOPA-PET compared with conventional imaging is confirmed in future studies, this imaging method could replace use of SRS, help improve prediction of prognosis, and be used to assess patients' response to treatment for carcinoid tumours. [ABSTRACT FROM AUTHOR]

Published
2006
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results